BACKGROUND AND PURPOSE: Marine sponges have evolved the capacity to produce a series of very efficient chemicals to combat viruses, bacteria, and eukaryotic organisms. It has been demonstrated that several of these compounds have anti-neoplastic activity. The highly toxic sponge Crambe crambe has been the source of several molecules named crambescidins. Of these, crambescidin-816 has been shown to be cytotoxic for colon carcinoma cells. To further investigate the potential anti-carcinogenic effect of crambescidin-816, we analysed its effect on the transcription of HepG2 cells by microarray analysis followed by experiments guided by the results obtained. EXPERIMENTAL APPROACH: After cytotoxicity determination, a transcriptomic analysis was performed to test the effect of crambescidin-816 on the liver-derived tumour cell HepG2. Based on the results obtained, we analysed the effect of crambescidin-816 on cell-cell adhesion, cell-matrix adhesion, and cell migration by Western blot, confocal microscopy, flow cytometry and transmission electron microscopy. Cytotoxicity and cell migration were also studied in a variety of other cell lines derived from human tumours. KEY RESULTS: Crambescidin-816 had a cytotoxic effect on all the cell lines studied. It inhibited cell-cell adhesion, interfered with the formation of tight junctions, and cell-matrix adhesion, negatively affecting focal adhesions. It also altered the cytoskeleton dynamics. As a consequence of all these effects on cells crambescidin-816 inhibited cell migration. CONCLUSIONS AND IMPLICATIONS: The results indicate that crambescidin-816 is active against tumour cells and implicate a new mechanism for the anti-tumour effect of this compound.
BACKGROUND AND PURPOSE: Marine sponges have evolved the capacity to produce a series of very efficient chemicals to combat viruses, bacteria, and eukaryotic organisms. It has been demonstrated that several of these compounds have anti-neoplastic activity. The highly toxic sponge Crambe crambe has been the source of several molecules named crambescidins. Of these, crambescidin-816 has been shown to be cytotoxic for colon carcinoma cells. To further investigate the potential anti-carcinogenic effect of crambescidin-816, we analysed its effect on the transcription of HepG2 cells by microarray analysis followed by experiments guided by the results obtained. EXPERIMENTAL APPROACH: After cytotoxicity determination, a transcriptomic analysis was performed to test the effect of crambescidin-816 on the liver-derived tumour cell HepG2. Based on the results obtained, we analysed the effect of crambescidin-816 on cell-cell adhesion, cell-matrix adhesion, and cell migration by Western blot, confocal microscopy, flow cytometry and transmission electron microscopy. Cytotoxicity and cell migration were also studied in a variety of other cell lines derived from humantumours. KEY RESULTS:Crambescidin-816 had a cytotoxic effect on all the cell lines studied. It inhibited cell-cell adhesion, interfered with the formation of tight junctions, and cell-matrix adhesion, negatively affecting focal adhesions. It also altered the cytoskeleton dynamics. As a consequence of all these effects on cells crambescidin-816 inhibited cell migration. CONCLUSIONS AND IMPLICATIONS: The results indicate that crambescidin-816 is active against tumour cells and implicate a new mechanism for the anti-tumour effect of this compound.
Authors: El Hassan Belarbi; Antonio Contreras Gómez; Yusuf Chisti; Francisco García Camacho; Emilio Molina Grima Journal: Biotechnol Adv Date: 2003-10 Impact factor: 14.227
Authors: Christian Bojarski; Jörg Weiske; Torsten Schöneberg; Werner Schröder; Joachim Mankertz; Jörg-Dieter Schulzke; Peter Florian; Michael Fromm; Rudolf Tauber; Otmar Huber Journal: J Cell Sci Date: 2004-03-30 Impact factor: 5.285
Authors: Víctor Martín; Carmen Vale; Stéphanie Bondu; Olivier P Thomas; Mercedes R Vieytes; Luís M Botana Journal: Chem Res Toxicol Date: 2013-01-09 Impact factor: 3.739
Authors: A Koff; A Giordano; D Desai; K Yamashita; J W Harper; S Elledge; T Nishimoto; D O Morgan; B R Franza; J M Roberts Journal: Science Date: 1992-09-18 Impact factor: 47.728
Authors: Zachary D Aron; Halina Pietraszkiewicz; Larry E Overman; Fredrick Valeriote; Carman Cuevas Journal: Bioorg Med Chem Lett Date: 2004-07-05 Impact factor: 2.823
Authors: Amr El-Demerdash; Atanas G Atanasov; Anupam Bishayee; Mamdouh Abdel-Mogib; John N A Hooper; Ali Al-Mourabit Journal: Nutrients Date: 2018-01-02 Impact factor: 5.717
Authors: Juan A Rubiolo; Emilio Lence; Concepción González-Bello; María Roel; José Gil-Longo; Manuel Campos-Toimil; Eva Ternon; Olivier P Thomas; Antonio González-Cantalapiedra; Henar López-Alonso; Mercedes R Vieytes; Luis M Botana Journal: Front Pharmacol Date: 2021-07-07 Impact factor: 5.810
Authors: María Roel; Juan A Rubiolo; Eva Ternon; Olivier P Thomas; Mercedes R Vieytes; Luis M Botana Journal: Mar Drugs Date: 2015-07-27 Impact factor: 5.118
Authors: Juan A Rubiolo; Eva Ternon; Henar López-Alonso; Olivier P Thomas; Félix V Vega; Mercedes R Vieytes; Luis M Botana Journal: Mar Drugs Date: 2013-11-08 Impact factor: 5.118
Authors: Sergey A Dyshlovoy; Kseniya M Tabakmakher; Jessica Hauschild; Regina K Shchekaleva; Katharina Otte; Alla G Guzii; Tatyana N Makarieva; Ekaterina K Kudryashova; Sergey N Fedorov; Larisa K Shubina; Carsten Bokemeyer; Friedemann Honecker; Valentin A Stonik; Gunhild von Amsberg Journal: Mar Drugs Date: 2016-07-15 Impact factor: 5.118